Enhertu is designed to target the HER2 protein, which helps cancer grow, divide and spread. HER2-positive breast cancer is an aggressive form of breast cancer.
In a clinical trial, 60.3 percent of patients saw tumor shrinkage.
The drug comes with a risk for interstitial lung disease as well as embryo-fetal toxicity.
The FDA advised that healthcare professionals monitor Enhertu patients for symptoms including cough, difficult or labored breathing, fever and other new or worsening respiratory symptoms. If such symptoms arise, Enhertu should be withheld, the dose reduced or the drug permanently discontinued.
Women who are pregnant should not take Enhertu because it may harm a developing fetus or newborn baby or cause delivery complications.
Enhertu was granted breakthrough therapy designation and fast-track designation.
Read the full news release here.
More articles on pharmacy:
Novartis plans giveaway of world’s most expensive drug
Albertsons launches 1- to 2-hour prescription deliveries
Smart Pharmacy lays off most of workforce
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.